These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 26627878)
21. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Vinereanu D; Wang A; Mulder H; Lopes RD; Jansky P; Lewis BS; Gersh BJ; Avezum A; Hanna M; Held C; Wallentin L; Granger CB; Alexander JH Heart; 2018 Aug; 104(15):1292-1299. PubMed ID: 29352007 [TBL] [Abstract][Full Text] [Related]
22. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Guimarães PO; Wojdyla DM; Alexander JH; Thomas L; Alings M; Flaker GC; Al-Khatib SM; Hanna M; Horowitz JD; Wallentin L; Granger CB; Lopes RD Int J Cardiol; 2017 Jan; 227():443-449. PubMed ID: 27852444 [TBL] [Abstract][Full Text] [Related]
23. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L; Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808 [TBL] [Abstract][Full Text] [Related]
24. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Hijazi Z; Wallentin L; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Pol T; Yusuf S; Oldgren J; Siegbahn A J Am Heart Assoc; 2020 Dec; 9(24):e018984. PubMed ID: 33292046 [TBL] [Abstract][Full Text] [Related]
25. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113 [TBL] [Abstract][Full Text] [Related]
27. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation. Mavrakanas TA; Garlo K; Charytan DM Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398 [TBL] [Abstract][Full Text] [Related]
28. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390 [TBL] [Abstract][Full Text] [Related]
29. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L; JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942 [TBL] [Abstract][Full Text] [Related]
30. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Yates SW Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322 [TBL] [Abstract][Full Text] [Related]
32. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. Horowitz JD; De Caterina R; Heresztyn T; Alexander JH; Andersson U; Lopes RD; Steg PG; Hylek EM; Mohan P; Hanna M; Jansky P; Granger CB; Wallentin L; J Am Coll Cardiol; 2018 Aug; 72(7):721-733. PubMed ID: 30092948 [TBL] [Abstract][Full Text] [Related]
33. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L; Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292 [TBL] [Abstract][Full Text] [Related]
34. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620 [TBL] [Abstract][Full Text] [Related]
35. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592 [TBL] [Abstract][Full Text] [Related]
37. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Ezekowitz JA; Lewis BS; Lopes RD; Wojdyla DM; McMurray JJ; Hanna M; Atar D; Cecilia Bahit M; Keltai M; Lopez-Sendon JL; Pais P; Ruzyllo W; Wallentin L; Granger CB; Alexander JH Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):86-94. PubMed ID: 27533976 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Goto S; Zhu J; Liu L; Oh BH; Wojdyla DM; Aylward P; Bahit MC; Gersh BJ; Hanna M; Horowitz J; Lopes RD; Wallentin L; Xavier D; Alexander JH; Am Heart J; 2014 Sep; 168(3):303-9. PubMed ID: 25173541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]